诺诚健华上半年药品收入达6.4亿元，亏损收窄86%

Core Insights - The company reported a 74.3% year-on-year increase in revenue for the first half of 2025, reaching 730 million yuan [1] - The revenue growth is primarily attributed to the continued expansion of the core product, Oubatinib, and the upfront payment received from the licensing agreement with Prolium [1] - Pharmaceutical revenue increased by 53.5% year-on-year to 640 million yuan, driven by Oubatinib's inclusion in the national medical insurance and its growing patient base, particularly in the exclusive indication of marginal zone lymphoma [1] - The company's loss narrowed significantly by 86.7% year-on-year to 36 million yuan, due to increased operating income and improved cost efficiency [1]